Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31524123 | 1.00 | THRA (0.33) | THRATHRBMAPTFEN1 | |
| SCHEMBL23421620 | 0.94 | FEN1 (0.35) | THRATHRBMAPTFEN1 | |
| SCHEMBL22632540 | 0.94 | FEN1 (0.37) | THRATHRBMAPTFEN1 | |
| SCHEMBL29414843 | 0.94 | FEN1 (0.37) | THRATHRBMAPTFEN1 | |
| SCHEMBL29986640 | 0.94 | FEN1 (0.35) | THRATHRBMAPTFEN1 | |
| SCHEMBL29987261 | 0.93 | THRB (0.35) | THRATHRBMAPTFEN1 | |
| SCHEMBL24032513 | 0.86 | MAPT (0.33) | MAPT | |
| SCHEMBL21840341 | 0.85 | THRA (0.33) | THRATHRB | |
| SCHEMBL23260087 | 0.85 | MAPT (0.32) | MAPT | |
| SCHEMBL30075045 | 0.85 | THRA (0.38) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC PHARMACEUTICALS INC (CN) | 2023-03-23 | — | — | US | disclosed |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS INC (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4083024-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2022-11-02 | — | — | EP | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | InventisBio Co., Ltd. (CN) | 2021-11-18 | — | — | US | disclosed |
| EP-3863635-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| CN-111484481-A | Pyridazinone derivative, preparation method and medical application thereof | 察略盛医药科技(上海)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885MAPT 2085/4885 |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885MAPT 2069/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885MAPT 2069/4885 |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | THRA 2/4885THRB 4/4885MAPT 3701/4885 |
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885MAPT 4344/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885MAPT 2069/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885MAPT 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.